BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.16.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260630T110000
DTEND;TZID=America/Los_Angeles:20260630T120000
DTSTAMP:20260619T000052Z
CREATED:20260529T135221Z
LAST-MODIFIED:20260619T000052Z
UID:10553-1782817200-1782820800@thebiocalendar.com
SUMMARY:The Evolution and Future of Targeted Protein Degradation Chemistry
DESCRIPTION:Once a fringe idea in chemical biology\, targeted protein degradation (TPD) has become one of the most watched strategies in drug discovery. TPD has created new therapeutic opportunities for previously undruggable protein targets. Leading experts will discuss the design\, challenges\, and clinical promise of PROTACs in overcoming limitations of traditional small molecules. \nEver wonder: \nHow have PROTACS\, molecular glues\, and linker chemistries and their related research and development evolved over the past 20 years? \nHow we decide on the right modality and MoA? \nWhich discovery technologies are available to us? \nHow do they translate from animals to humans? \nHow are companies and academic groups approaching safety assessment for degraders\, particularly with respect to off‑target effects\, tissue specificity\, and long‑term protein knockdown? \nJoin us to get some answers directly from field experts.
URL:https://thebiocalendar.com/event/the-evolution-and-future-of-targeted-protein-degradation-chemistry/
LOCATION:Online webinar
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260630T110000
DTEND;TZID=America/Los_Angeles:20260630T120000
DTSTAMP:20260618T235913Z
CREATED:20260615T145041Z
LAST-MODIFIED:20260618T235913Z
UID:10608-1782817200-1782820800@thebiocalendar.com
SUMMARY:Breaking the Titer Ceiling: Smarter Media Design for Higher Productivity
DESCRIPTION:Discover how innovative media design strategies can help overcome productivity limitations in bioprocessing and drive higher titers without sacrificing product quality. In this webinar\, experts will share a data-driven\, bottom-up approach to media development using Design of Experiments (DOE) to identify the nutrients that have the greatest impact on cell culture performance. Learn how optimized basal and feed formulations can improve culture robustness\, alleviate metabolic bottlenecks\, and enhance productivity while maintaining critical quality attributes and process consistency.
URL:https://thebiocalendar.com/event/breaking-the-titer-ceiling-smarter-media-design-for-higher-productivity/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/06/06-30-26-KBI-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260630T120000
DTEND;TZID=America/Los_Angeles:20260630T130000
DTSTAMP:20260618T235845Z
CREATED:20260528T122037Z
LAST-MODIFIED:20260618T235845Z
UID:10540-1782820800-1782824400@thebiocalendar.com
SUMMARY:Residual DNA testing across biotherapeutics: dPCR workflows and a CDMO perspective
DESCRIPTION:Residual host cell DNA (residual DNA) is a critical quality attribute across biologics\, vaccines and advanced therapy modalities\, requiring sensitive and reproducible quantification to support process development\, in-process control and lot release. However\, traditional workflows can introduce variability and delay release timelines due to reliance on standard curves\, multiple manual steps and method complexity. \nIn this webinar\, we will outline digital PCR (dPCR) workflows and performance for residual DNA analysis across a range of expression systems\, including Vero\, Sf9/Baculovirus\, Pichia pastoris\, mouse\, HEK293\, CHO and E. coli. We will discuss how a standardized dPCR approach can simplify method deployment across diverse programs. \nKBI Biopharma will share real-life perspectives on implementing dPCR-based residual DNA workflows for CHO- and E. coli-derived programs\, including considerations for sample preparation and data interpretation. The session will also explore how extraction-free dPCR workflows can streamline in-process monitoring and lot release testing\, enabling faster decision-making and improved manufacturing efficiency. The webinar will conclude with practical guidance on assay selection and integration of residual DNA testing into development and manufacturing workflows. \nLearning objectives:\n– Understand dPCR-based residual DNA workflows and performance across multiple expression systems\n– Evaluate how dPCR can improve workflow efficiency and data quality\, including accuracy\, linearity\, and reduced turnaround time\n– Learn from a CDMO case study on implementing residual DNA testing\, including comparison to qPCR and the impact of extraction-free workflows on in-process monitoring and lot release
URL:https://thebiocalendar.com/event/residual-dna-testing-across-biotherapeutics-dpcr-workflows-and-a-cdmo-perspective/
LOCATION:Online webinar
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/05/06-30-26-Qiagen-Reg-1920x250-1.png
END:VEVENT
END:VCALENDAR